Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

Javelin Pharmaceuticals Signs Supply Pact with Baxter Healthcare

  • Baxter Healthcare inked a commercial supply agreement with Javelin Pharmaceuticals to provide additional manufacturing capacity for Javelin's injectable diclofenac, Dyloject™.

    Dylojectinjectable diclofenac sodium is under review for marketing approval in the U.K. for the treatment of acute moderate-to-severe pain. In the U.S., Dyloject is in Phase III trials for the same indication.

    Baxter will serve as a secondary manufacturer of Dyloject pending regulatory approval. The deal, which supplements an existing collaboration, has a three-year, renewable term and sets forth minimum purchase and production requirements.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »